| Biomarker ID | 459 |
| PMID | 19491931 |
| Year | 2009 |
| Biomarker | IGF1 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | NA |
| Subjects | Humans |
| Regulation | Higher concentrations in patients with increased risk of prostate cancer |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: 1.24 (95% CI: 1.01 - 1.53) |
| Effect on Pathways | Pathways Include:-Skeletal myogenesis control by HDAC and calcium/calmodulin-dependent kinase (CaMK),BAD phosphorylation regulation,Fibroblast growth factor 1,IGF1 signaling pathway,IGF1 receptor signaling through beta-arrestin |
| Experiment | NA |
| Type of Biomarker | Diagnostic |
| Cohort | Meta analysis of 21 studies using, IGF1 and IGFBP3 as marker to predict prostate cancer risk. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.049 |
| Method Used | NA |
| Clinical | No |
| Remarks | Metastudy |
| Clinical Trial Number | NA |
| Degree Of Validity | Metanalysis from 96 studies |
| Technical Name | IGF1 |